Allied Biotech Corporation

TPEX:1780 Stok Raporu

Piyasa değeri: NT$1.6b

Allied Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Allied Biotech has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 3.7% per year. Allied Biotech's return on equity is 9.1%, and it has net margins of 13.8%.

Anahtar bilgiler

5.6%

Kazanç büyüme oranı

5.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi12.2%
Gelir büyüme oranı3.7%
Özkaynak getirisi9.1%
Net Marj13.8%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

Apr 16
Is Allied Biotech Corporation (GTSM:1780) A Good Dividend Stock?

These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Mar 05
These 4 Measures Indicate That Allied Biotech (GTSM:1780) Is Using Debt Reasonably Well

Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Jan 24
Allied Biotech (GTSM:1780) Has Compensated Shareholders With A Respectable 49% Return On Their Investment

Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

Jan 03
Is Allied Biotech Corporation (GTSM:1780) At Risk Of Cutting Its Dividend?

A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Dec 13
A Look At The Intrinsic Value Of Allied Biotech Corporation (GTSM:1780)

Is Allied Biotech (GTSM:1780) A Risky Investment?

Nov 25
Is Allied Biotech (GTSM:1780) A Risky Investment?

Gelir ve Gider Dağılımı

Allied Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TPEX:1780 Gelir, gider ve kazançlar (TWD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2476910613626
31 Mar 2474510213426
31 Dec 237209713226
30 Sep 2372812113726
30 Jun 2373614414226
31 Mar 2372714514525
31 Dec 2271714714725
30 Sep 2269910513925
30 Jun 226816213125
31 Mar 226793812626
31 Dec 216771312126
30 Sep 216583211725
30 Jun 216395111425
31 Mar 216296511425
31 Dec 206187911425
30 Sep 206137211324
30 Jun 206086511224
31 Mar 206248611324
31 Dec 1963910711424
30 Sep 1967012012024
30 Jun 1970013412724
31 Mar 1972813813324
31 Dec 1876513313125
30 Sep 1876412412727
30 Jun 1876311412429
31 Mar 187159911530
31 Dec 176827111428
30 Sep 176455312726
30 Jun 176093513923
31 Mar 176032913523
31 Dec 165744013323
30 Sep 165635412024
30 Jun 165526810725
31 Mar 165385711226
31 Dec 155244611628
30 Sep 155163011828
30 Jun 155091312128
31 Mar 154921012227
31 Dec 14474712426
30 Sep 144881112326
30 Jun 145021512125
31 Mar 144911111825
31 Dec 13480611524

Kaliteli Kazançlar: 1780 has high quality earnings.

Büyüyen Kar Marjı: 1780's current net profit margins (13.8%) are lower than last year (19.5%).

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1780's earnings have grown by 5.6% per year over the past 5 years.

Büyüme Hızlandırma: 1780's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: 1780 had negative earnings growth (-26.4%) over the past year, making it difficult to compare to the Biotechs industry average (33.2%).

Özkaynak Getirisi

Yüksek ROE: 1780's Return on Equity (9.1%) is considered low.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y